（文章来源：证券日报） 证券日报网讯海特生物8月21日在互动平台回答投资者提问时表示，公司主要在研产品及其相关进展在 定期报告中进行了公告，详细情况请关注公司的定期报告。 ...

Group 1 - The company, Hite Bio, reported that as of August 20, the number of shareholders is 13,430 [1]

Market Overview - On August 21, the medical services sector declined by 0.15%, with Haitai Biological leading the drop [1] - The Shanghai Composite Index closed at 3771.1, up 0.13%, while the Shenzhen Component Index closed at 11919.76, down 0.06% [1] Stock Performance - Notable gainers in the medical services sector included: - Bid Medicine (688073) with a closing price of 63.23, up 5.31% on a trading volume of 20,200 shares and a turnover of 124 million yuan [1] - Chengda Pharmaceutical (301201) closed at 31.40, up 3.90% with a trading volume of 84,300 shares and a turnover of 266 million yuan [1] - Aoyang Health (002172) closed at 4.44, up 3.74% with a trading volume of 829,800 shares and a turnover of 368 million yuan [1] - Major decliners included: - Haitai Biological (300683) closed at 50.73, down 4.17% with a trading volume of 78,000 shares and a turnover of 404 million yuan [2] - Sanbo Brain Science (301293) closed at 61.25, down 3.88% with a trading volume of 164,100 shares and a turnover of 1.009 billion yuan [2] - Haochen Medical (002622) closed at 3.83, down 3.28% with a trading volume of 997,600 shares and a turnover of 386 million yuan [2] Capital Flow - The medical services sector experienced a net outflow of 821 million yuan from institutional investors, while retail investors saw a net inflow of 528 million yuan [2][3] - Key stocks with significant capital flow included: - Jinkai Biotechnology (301509) with a net inflow of 57.64 million yuan from institutional investors [3] - Huada Gene (300676) saw a net outflow of 23.72 million yuan from retail investors [3] - Aoyang Health (002172) had a net inflow of 23.03 million yuan from institutional investors [3]

Group 1 - The company, HaiTe Bio (300683.SZ), has recently obtained a revised "Drug Production License" from the Hubei Provincial Drug Administration [1] - The change primarily involves the reduction of the entrusted production relationship with Hubei Sihuan Pharmaceutical Co., Ltd., while other contents of the license remain unchanged [1]

证券代码：300683 证券简称：海特生物 公告编号：2025-030 武汉海特生物制药股份有限公司 关于使用闲置募集资金购买理财产品的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 武汉海特生物制药股份有限公司（以下简称"公司"）于 2024 年 11 月 12 日召开第八届董事会第十九次会议、第八届监事会第十九次会议，会议审议通过 了《关于使用闲置募集资金及自有资金进行现金管理的议案》，同意公司在确保 不影响募集资金投资项目建设、不影响正常经营及确保资金安全的情况下，使用 不超过人民币 110,000 万元的资金购买投资期限不超过 12 个月，安全性高、流 动性好的低风险理财产品。其中，闲置募集资金的使用额度不超过人民币 45,000 万元，自有资金的使用额度不超过人民币 65,000 万元，本事项在董事会审议权 限内，无需提交股东大会审议，不构成关联交易。在上述额度内，资金可以滚动 使用，期限为 1 年。具体内容详见公司于 2024 年 11 月 12 日在巨潮资讯网（http： //www.cninfo.com.cn）披露的《关于使用闲置募集 ...

证券代码：300683 证券简称：海特生物 公告编号：2025-031 武汉海特生物制药股份有限公司（以下简称"公司"）于近日取得湖北省药 品监督管理局换发的《药品生产许可证》，同意《药品生产许可证》的变更申请。 本次变更主要涉及核减与受托方湖北四环制药有限公司相关药品的委托生产关 系，其他内容不变。变更后的《药品生产许可证》具体内容如下： 一、《药品生产许可证》基本情况 企业名称：武汉海特生物制药股份有限公司 注册地址：武汉经济技术开发区海特科技园 社会信用代码：91420100724667038L 法定代表人：陈亚 武汉海特生物制药股份有限公司 关于公司药品生产许可证变更的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 企业负责人：陈亚 质量负责人：赵满岐 许可证编号：鄂 20200224 二、对公司的影响及风险提示 公司本次核减与受托方湖北四环制药有限公司相关药品的委托生产关系，以 上变更对公司业绩无重大影响，敬请广大投资者理性投资，注意投资风险。 三、备查文件 分类码：AshCh 生产地址和生产范围：1.湖北省武汉经济技术开发区海特科技园 治疗用 ...

海特生物8月21日披露，截至8月20日公司股东户数为13430户，较上期（8月10日）减少1003户，环比降 幅为6.95%。这已是该公司股东户数连续第2期下降。 证券时报·数据宝统计，截至发稿，海特生物最新股价为51.16元，下跌3.36%，本期筹码集中以来股价 累计上涨0.59%。具体到各交易日，4次上涨，5次下跌。 公司发布的一季报数据显示，一季度公司共实现营业收入1.57亿元，同比增长18.79%，实现净利 润-1393.04万元，同比增长15.81%，基本每股收益为-0.1100元。（数据宝） 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 （文章来源：证券时报网） ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688265 | 南模生物 | 65.00 | -8.32% | 4.65万 | 3.07亿 | | 002173 | 创新医疗 | 24.84 | -6.97% | 147.80万 | 37.90亿 | | 652509 | 药明康德 | 90.26 | -6.93% | 131.17万 | 123.20亿 | | 300683 | 海特生物 | 54.33 | -4.58% | 15.33万 | 8.89亿 | | 688046 | 药康生物 | 18.08 | -4.49% | 6.06万 | 1.12亿 | | 301096 | 百诚医药 | 54.66 | -4.31% | 12.34万 | 6.85亿 | | 002622 | 皓宸医疗 | 3.60 | -3.74% | 80.54万 | 2.91亿 | | 688202 | 美迪西 | 64.23 | -3.70% | 10.89万 | 7.38亿 | | 300347 | 泰格医药 ...

Group 1 - The restructuring protein sector is leading the market with an increase of 3.07% [1] - Key companies in this sector include Kaiyin Technology, which rose by 8.7%, and Saiseng Pharmaceutical, which increased by 7.3% [1] - Other notable performers are Maiwei Biotechnology with a rise of 6.86%, and Baipusais, Hite Biotechnology, and Ruizhi Pharmaceutical, all of which saw gains exceeding 4% [1]

Group 1 - The A-share market saw a significant rise in pharmaceutical stocks, with notable performances including Furuide Co., Ltd. hitting a 20% limit up, and Boji Pharmaceutical rising by 14% [1] - Other companies such as Jimin Health and Kangyuan Pharmaceutical also experienced substantial gains, with both reaching a 10% limit up [1] - The overall trend indicates a bullish sentiment in the pharmaceutical sector, with multiple stocks showing increases of over 5% [1] Group 2 - Furuide Co., Ltd. reported a market capitalization of 19.1 billion and a year-to-date increase of 129.01% [2] - Boji Pharmaceutical had a market cap of 4.819 billion and a year-to-date increase of 43.33% [2] - Other notable companies include Jimin Health with a market cap of 5.66 billion and a year-to-date increase of 58.76%, and Kangyuan Pharmaceutical with a market cap of 11.2 billion and a year-to-date increase of 45.59% [2]